

Autologous Stem Cell Therapy's Advancements Impact on Childhood Traumatic Brain Injury

Thomas Joseph*

Department of Cardiology, Duke University, Durham, USA

DESCRIPTION

Childhood Traumatic Brain Injury (TBI) represents a significant public health concern, with long-lasting consequences that can affect cognitive, behavioral, and physical functions. Conventional treatments for childhood TBI often focus on symptomatic relief rather than promoting regeneration and repair. However, emerging therapies, such as autologous stem cell therapy, offer promising avenues for improving outcomes in children with TBI [1]. This short communication aims to provide an overview of the potential benefits and challenges associated with autologous stem cell therapy in treating childhood TBI, followed by a concluding remark on its future prospects. Autologous stem cell therapy involves the use of a patient's own stem cells for therapeutic purposes [2-6]. In the context of childhood TBI, this therapy harnesses the regenerative potential of stem cells to promote brain tissue repair and functional recovery. Autologous stem cells can be derived from various sources, including bone marrow, adipose tissue, or umbilical cord blood. These cells possess the unique ability to differentiate into different cell types, replace damaged cells, modulate inflammation, and secrete neurotrophic factors that promote neuronal survival and regeneration. Preclinical and early clinical studies have demonstrated the safety and potential efficacy of autologous stem cell therapy in childhood TBI [7].

Animal studies have shown that stem cell transplantation can improve neurological outcomes, reduce neuronal loss, and enhance neurogenesis in TBI models. Furthermore, early-phase clinical trials have reported encouraging results, with improved cognitive and functional outcomes observed in children who received autologous stem cell therapy. Several mechanisms underlie the therapeutic effects of autologous stem cell therapy in childhood TBI. Firstly, transplanted stem cells can differentiate into neurons and other brain cells, replacing damaged tissue and restoring neural circuitry. Secondly, these cells release trophic factors that promote angiogenesis, neuroprotection, and neuroregeneration. Thirdly, stem cells modulate the inflammatory response, reducing secondary damage and creating

an environment conducive to healing. Additionally, stem cells may have immunomodulatory properties, regulating immune cell function and promoting tissue repair. Despite these promising findings, challenges remain in implementing autologous stem cell therapy for childhood TBI. The optimization of stem cell transplantation protocols, including the timing, route, and dosage of cell administration, requires further investigation. Ensuring long-term safety and monitoring potential adverse effects are crucial considerations. Additionally, ethical and regulatory frameworks must be established to govern the use of stem cell therapies in pediatric populations.

CONCLUSION

Childhood traumatic brain injury shows significant potential for treatment through autologous stem cell therapy. Preclinical and early clinical studies have demonstrated the regenerative potential of stem cells in promoting neurological recovery. The multifaceted mechanisms of action, including cell replacement, trophic factor secretion, and immunomodulation, contribute to the therapeutic effects observed. However, several challenges, such as protocol optimization, safety monitoring, and ethical considerations, need to be addressed before widespread implementation. Moving forward, continued research efforts, including well-designed clinical trials and longitudinal studies, are necessary to establish the long-term safety, efficacy, and optimal treatment protocols of autologous stem cell therapy for childhood TBI. Collaborative efforts between scientists, clinicians, regulatory authorities, and ethicists are essential for advancing this field and ensuring the responsible translation of this promising therapy into clinical practice. With further advancements, autologous stem cell therapy may offer a transformative approach to improve outcomes and enhance the quality of life for children affected by traumatic brain injury.

REFERENCES

1. Cox Jr CS, Hetz RA, Liao GP, Aertker BM, Ewing Cobbs L, Juranek J, et al. Treatment of severe adult traumatic brain injury using bone marrow mononuclear cells. *Stem Cells*. 2017;35(4):1065-1079.

Correspondence to: Thomas Joseph, Department of Cardiology, Duke University, Durham, USA, E-mail: povsi03@mc.duke.edu

Received: 02-May-2023; Manuscript No. JCEST-23-24431; **Editor assigned:** 05-May-2023; Pre-Qc No JCEST-23-24431 (PQ); **Reviewed:** 19-May-2023; QC No. JCEST-23-24431; **Revised:** 29-May-2023, Manuscript No. JCEST-23-24431 (R); **Published:** 05-Jun-2023, DOI: 10.35248/2157-7013.23.14.397

Citation: Joseph T (2023) Autologous Stem Cell Therapy's Advancements Impact on Childhood Traumatic Brain Injury. *J Cell Sci Therapy*. 14:397.

Copyright: © 2023 Joseph T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

2. Hasan A, Deeb G, Rahal R, Atwi K, Mondello S, Marei HE, et al. Mesenchymal stem cells in the treatment of traumatic brain injury. *Front Neurol.* 2017;20(8):28.
3. Mead B, Logan A, Berry M, Leadbeater W, Scheven BA. Intravitreally transplanted dental pulp stem cells promote neuroprotection and axon regeneration of retinal ganglion cells after optic nerve injury. *IOVS.* 2013;54(12):7544-7556.
4. Khalili MA, Anvari M, Hekmati-Moghadam SH, Sadeghian-Nodoushan F, Fesahat F, Miresmaeili SM. Therapeutic benefit of intravenous transplantation of mesenchymal stem cells after experimental subarachnoid hemorrhage in rats. *J Stroke Cerebrovasc Dis.* 2012;21(6):445-451.
5. Cox Jr CS, Baumgartner JE, Harting MT, Worth LL, Walker PA, Shah SK, et al. Autologous bone marrow mononuclear cell therapy for severe traumatic brain injury in children. *Neurosurg.* 2011;68(3):588-600.
6. Segal GH, Karvat G, Barak N, Barzilay R, Ganz J, Edry L, et al. Mesenchymal stem cell transplantation promotes neurogenesis and ameliorates autism related behaviors in BTBR mice. *Autism Res.* 2016;9(1):17-32.
7. Walker PA, Bedi SS, Shah SK, Jimenez F, Xue H, Hamilton JA, et al. Intravenous multipotent adult progenitor cell therapy after traumatic brain injury: modulation of the resident microglia population. *J Neuroinflammation.* 2012;9(1):1-3.